Fungal Infections Complicating Tumor Necrosis Factor a Blockade Therapy

Tsiodras, Sotirios; Samonis, George; Boumpas, Dimitrios T.; Kontoyiannis, Dimitrios P.
February 2008
Mayo Clinic Proceedings;Feb2008, Vol. 83 Issue 2, p181
Academic Journal
Tumor necrosis factor α (TNF-α) blockade has emerged as a useful therapy for collagen vascular diseases or graft-vs-host disease. Fungal Infections complicating such therapy have been reported sporadically. MEDLINE and PubMed databases (from January 1, 1966, to June 1, 2007) were searched for reports of Invasive fungal Infections (IFIs) associated with the 3 available antl-TNF-α agents, le, infliximab, etanercept, and adalimumab. Of the 281 cases of IFI associated with TNF-α Inhibition, 226 (80%) were associated with Infliximab, 44 (16%) with etanercept, and 11 (4%) with adailmumab. Fungal Infections associated with infliximab occurred a median of 55 days (Interquartile range [IQR], 15-140 days) after Initiation of therapy and 3 infusions of the medication (IQR, 2-5), whereas those associated with etanercept occurred a median of 144 days (1QR, 46-240 days) after initiation of therapy. The median age of patients was 58 years (1QR, 44-68 years), and 62% were male. Use of at least I other Immunosup-pressant medication, typically a systemic corticosterold, was reported during the course of the fungal Infection In 102 (98%) of the 104 patients for whom data were available. The most prevalent IFis were histoplasmosis (n=84 [30%]), candidiasis (n=64 [23%]), and aspergiliosis (n=64 [23%]). Pneumonia was the most common pattern of Infection. Of the 90 (32%) of 281 cases for which outcome Information was available, 29 fatalities (32%) were recorded. Tumor necrosis factor a blockade Is associated with IFI across a range of host groups. A high index of suspicion In patients treated with TNF-α antagonists Is recommended because the course of such Infections can be serious or fulminant, and rapid access to health care should be provided. Surveillance of IFIs complicating TNF-a blockade and other biologic therapies Is war- ranted through well-organized prospective patient registries.


Related Articles

  • Immune suppression and infections.  // Mayo Clinic Health Letter;Feb2013, Vol. 31 Issue 2, p4 

    The article focuses on immune suppression and infections. It states that if the immune system is suppressed or not working properly, you may face a greater risk of getting infected, and the suppression can occur for a number of reasons which include corticosteroid therapy, cancer treatment, or...

  • Psoriasis's changing face. Petrou, IIya // Dermatology Times;Jul2009, Vol. 30 Issue 7, p91 

    The article offers information related to psoriasis, including its history, current treatment and biologics. It mentions that psoriasis is well known in 1841 and its tropical treatment for localized psoriasis can include tar, topical corticosteroids, topical calcipotriene and topical tazarotene....

  • Review on Pulse Therapy: A Novel Approach in the Treatment of Pemphigus Vulgaris. Kaul, Rachna; Sanjay, C. J. // Journal of Indian Academy of Oral Medicine & Radiology;Oct-Dec2010, Vol. 22 Issue 4, p211 

    Objective: Pemphigus vulgaris, a fatal autoimmune mucocutaneous disorder commonly seen involving the oral cavity, has since a long time remained a topic of concern regarding its treatment modalities. Pulse therapy, introduced in 1984, employs high-dose corticosteroids along with certain...

  • The Changing Face of Spondyloarthropathies Under TNF α Blockade. Elkayam, Ori; Litinsky, Irena; Levartovsky, David; Caspi, Dan // Open Rheumatology Journal;2008, Vol. 2, p53 

    Objectives: Tumor necrosis factor alpha (TNF-α) therapy has been implicated in the development of autoimmune diseases. Our aim was to describe three patients with spondyloarthropathies who responded to infliximab, a chimeric monoclonal antibody specific for TNF-α, but developed new...

  • Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Toshio Tanaka; Yoshihiro Hishitani; Atsushi Ogata // Biologics: Targets & Therapy;2014, Vol. 8, p141 

    Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation, systemic inflammation, and immunological abnormalities. Because cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 play a major role in the development of RA, their...

  • Adalimumab in Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 2, p133 

    The article presents the author's views regarding the use of adalimumab for treatment of patients with Crohn's disease. He asserts that with the introduction of tumor necrosis factor-neutralizing antibodies such as infliximab and adalimumab, patients with Crohn' disease who start failing to...

  • SPONDYLOARTHROPATHY.  // Current Medical Literature: Rheumatology;2004, Vol. 23 Issue 1, p16 

    Presents a clinician's note on the study "Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?," conducted by D. Baeten, et al, and published in a 2003 issue of...

  • Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Freeman, Hugh J. // Therapeutics & Clinical Risk Management;2013, Vol. 9, p451 

    In selected patients with moderate to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corticosteroids and immunosuppressive agents, therapy with a biological agent may be considered. While infliximab is an...

  • Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF Agents for Behçet´s disease: analysis of published data on 369 patients. Semin Arthritis Rheum [PMID:21168186]. Stuebiger, Nicole; Hazirolan, Dicle; Pleyer, Uwe // Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2011, Vol. 249 Issue 9, p1273 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics